A CME Symposium during the 2026 Heart Failure Management Conference in Fernandina Beach, Florida.

AGENDA

8:00 am                          Introduction
                                       Muthiah Vaduganathan, MD, MPH (Chair)

8:05 am                          Hyperkalemia and Heart Failure: Impact of Continuation/Discontinuation of RAASi Therapy
                                       Akshay Desai, MD, MPH

8:20 am                          Treating Hyperkalemia and Optimizing RAASi in HF Patients with Potassium Binders
                                       Muthiah Vaduganathan, MD, MPH

8:35 am                          Best Strategies for Managing My HFrEF Patient with Elevated Potassium and a History of Hyperkalemia
                                       Case Presenter: Robert Page, PharmD, MSPH, BCPS, BCGP
                                       Panelists: Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC; Akshay Desai, MD, MPH; Muthiah Vaduganathan, MD, MPH

8:50 am                          Question-and-Answer

EDUCATIONAL OBJECTIVES

•  Recognize heart failure patients at risk for developing hyperkalemia

•  Describe the relationship between hyperkalemia, suboptimal RAASi therapy and poor clinical outcomes

•  Explain the data with, and demonstrate prudent use of novel potassium binders

Educational Grant

Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals.

CHAIR

Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Assistant Professor of Medicine
Mass General Brigham and Harvard Medical School
Boston, Massachusetts

FACULTY

Nancy Albert, PhD, CCNS, CHFN, CCRN, NE-BC
Associate Chief Nursing Officer--Research and Innovation
Clinical Nurse Specialist--Kaufman Center for Heart Failure
Cleveland Clinic
Cleveland, Ohio

Akshay Desai, MD, MPH
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Robert Page, PharmD, MSPH, BCPS, BCGP
Professor, Departments of Clinical Pharmacy and Physical Medicine
Skaggs School of Pharmacy and Pharmaceutical Sciences
CU Anschutz
Aurora, Colorado

A CME Symposium during the 2026 Heart Failure Management Conference in Fernandina Beach, Florida.

AGENDA

12:30 PM                       Introduction
                                      Mathew Maurer, MD (Chair)

12:35 PM                      Suspecting and Diagnosing Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
                                      Jan Griffin, MD

12:50 PM                      Best Practices for Managing Patients with HF and ATTR-CM
                                      Mathew Maurer, MD

1:10 PM                         Individualized Management of the ATTR-CM Patient with HF
                                      Case Presenter: Frederick Ruberg, MD
                                      Panelists: Jan Griffin, MD; Mathew Maurer, MD

1:25 PM                        Question and Answer

EDUCATIONAL OBJECTIVES

- Recognize the cardiac and extracardiac red fl ags which raise suspicion for ATTR-CM.

- Describe the diagnostic testing components to quickly and accurately diagnose ATTR-CM.

- Summarize current recommendations for use of HF GDMT in ATTR-CM patients and the evolving evidence for Silencers and Stabilizers for ATTR-CM.

- Identify the recommended parameters for monitoring disease progression in ATTR-CM.

Educational Grant

This activity is supported by an independent educational grant from Alnylam Pharmaceuticals, Inc. and BridgeBio.

CHAIR

Mathew Maurer, MD
Arnold and Arlene Goldstein Professor of Cardiology
Professor of Medicine
Columbia University Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York

FACULTY

Jan Griffin, MD
Associate Professor of Medicine
Medical University of South Carolina
Charleston, South Carolina

Frederick Ruberg, MD
Thomas J. Ryan Professor of Cardiovascular Medicine
Chief, Cardiovascular Medicine
Professor of Radiology
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, Massachusetts